Dr. med. Ansgar Felbecker
CELIA (Phase 2)
01.03.2024A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Klinische Forschung - 01.03.2024 - 31.12.2026
Laufend
Projektleitung: Felbecker Ansgar
Mitarbeiter/innen: Göhl-Freyn Kristina
Memory Clinic Cohort Study
01.03.2024Dementia is a clinical syndrome defined by a progressive cognitive decline interfering with a person's daily life and activities which is caused by a group of heterogenous neurodegenerative and neurovascular diseases which often overlap. Since patho...
Klinische Forschung - 01.03.2024 - 31.12.2040
Laufend
Projektleitung: Schneider Thomas, Felbecker Ansgar
Mitarbeiter/innen: Göhl-Freyn Kristina, Schilg-Hafer Lenka
Inflammatory Neuropathy Consortium Base (INCbase
15.12.2021The Inflammatory Neuropathy Consortium Base (INCbase) is an international registry for CIDP patients led by an international collaboration of CIDP experts. INCbase provides a state of the art modular research database that members may use to collect...
Grundlagenforschung - 15.12.2021 - 15.12.2025
Laufend
Mitarbeiter/innen: Felbecker Ansgar, Leupold Daniela
Cognitive Outcome 1 year after COVID-19 – A Pilot Study (CogCOVID)
19.10.2021This prospective observational pilot study examines cognitive function 1 year after SARS-Cov-2 disease. Study population consists of formerly hospitalized non-ventilated COVID-19 patients (nvCOVID) and ventilated patients with COVID-19-ARDS (cARDS) t...
Klinische Forschung - 19.10.2021 - 31.12.2022
Automatisch geschlossen
Projektleitung: Göhl-Freyn Kristina, Felbecker Ansgar
Mitarbeiter/innen: Albrich Werner, Schmid Dagmar, Kleger Gian-Reto, Schrag Claudia, Pietsch Urs
EVOKE
30.09.2021A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) This study is done to find out whether semaglutide has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo - w...
Klinische Forschung - 30.09.2021 - 31.12.2025
Laufend
Projektleitung: Felbecker Ansgar
Pilot study on cognitive and social function measures for early detection of progressive neurocognitive disorders in Switzerland
12.05.2021
Klinische Forschung - 12.05.2021 - 15.09.2022
Abgeschlossen
Projektleitung: Felbecker Ansgar
Development of a non-invasive screening system for the early detection of mild cognitive impairments in older adults
01.11.2020In dem geförderten Kooperationsprojekt “Development of a non-invasive screening system for the early detection of mild cognitive impairments in older adults” wird untersucht, ob ein multimodales nicht-invasives Testsystem geeignet ist, um frühe Stadi...
Klinische Forschung - 01.11.2020 - 01.07.2021
Automatisch geschlossen
Projektleitung: Felbecker Ansgar
Mitarbeiter/innen: Schneider Thomas
CRiPSI/CRiPSI-X: Covid-19 Risk Prediction in Swiss ICUs-Trial/Extension
01.08.2020Outcome of patients with critical Covid-19 varies. We study risk of and predictors for poor outcome in adult patients with Covid-19 admitted to ICU in a multicenter study. In addition, we assess the prevalence of, risk factors for and mechanisms invo...
Klinische Forschung - 01.08.2020 - 31.08.2022
Automatisch geschlossen
Projektleitung: Albrich Werner
Mitarbeiter/innen: Von Mering Christian, O'Mahony Liam, Cerny Andreas, Suh Noémie, El Baz Yassir, Dietrich Tobias, Fischer Tim, Felbecker Ansgar, Göhl-Freyn Kristina, Germann Nicolas, Schmid Dagmar, Kahlert Christian, Frischknecht Manuel, Filipovic Miodrag, Brutsche Martin, Pietsch Urs, Kleger Gian-Reto, Bochud Pierre-Yves
A3BAD study - Analysis of amyloid aggregates in blood with atomic force microscopy as a biomarker of Alzheimer Dementia
01.06.2020Background: The key neuropathological feature of Alzheimer disease (AD) is the accumulation of extracellular β-amyloid (Aβ) plaques in the brain which begins long before clinical signs of dementia. Immunotherapies targeting Aβ may prevent Aβ accumula...
Grundlagenforschung - 01.06.2020 - 30.05.2022
Automatisch geschlossen
Projektleitung: Felbecker Ansgar
Mitarbeiter/innen: Schneider Thomas, Nirmjaraj Peter
Randomisierte, doppelblinde, placebokontrollierte klinische Prüfung der Phase III mit Parallelgruppen zur Beurteilung der Wirksmkeit und Sicherheit von Desmoteplase bei Patienten mit akuten ischämischem Schlaganfall DIAS III
12.03.2010Multizentrische Therapiestudie zur Anwednung von Desmoteplase
Klinische Forschung - 12.03.2010 - 31.12.2012
Abgebrochen
Projektleitung: Weder Bruno, Kägi Georg
Mitarbeiter/innen: Hundsberger Thomas, Felbecker Ansgar, Hägele-Link Stefan, Galovic Marian, Leupold Daniela